BOULDER, Colo., Feb. 12, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, today announced that it has entered into a broad strategic collaboration with Genosity Inc., a biotechnology company that provides expertise, software and technical solutions to unlock the power of precision medicine by advancing genomics and facilitating collaborative research.
Under the terms of the collaboration, ArcherDX will co-market Genosity's suite of consulting and laboratory software services designed to facilitate implementation and speed adoption of next-generation sequencing based testing to support precision medicine programs across biopharmaceuticals and health systems. These services span the full lifecycle of genomic test development including assay and bioinformatics design assistance, validation planning and execution services, variant interpretation support and revenue cycle management optimization.
The software solutions covered under this collaboration include Genosity's Genome Explorer, Laboratory Information Management System (LIMS) and Cortex applications. The Genome Explorer platform integrates with and extends ArcherDX's Archer Analysis Unlimited bioinformatics pipeline with additional Case Analyzer and Report Builder modules that together provide an end-to-end computational analysis and result reporting solution for next-gen sequencing-based panels. The LIMS application is designed specifically for NGS workflows to improve laboratory efficiency while enabling quality control monitoring. Pre-configuration of most of the ArcherDX assays in Genosity's LIMS facilitates easier implementation of wet lab workflows in NGS labs. Genosity's Cortex provides a data warehouse and knowledge base that enables population-level analysis and cohort identification to support R&D and inter and intra-institution collaborations.
"The adoption of genomics must be made simpler and more cost-effective. From a clinical laboratory perspective, I have been intimately involved in virtually every aspect of next-gen sequencing over the past 15 years and without question, knowledge-based informatics and genomics are inextricably intertwined," said Dr. Marc D. Grodman, MD, co-founder and chief executive officer of Genosity. "Genosity has created robust solutions with both germline and somatic applications that can meet the broad needs of the genomics market. We are enthusiastic to work with Archer on incorporating their best of breed assays into our novel end-to-end software solution. Archer's lineage, scientific and technical expertise allows them to stand out in this distributive model of genomic testing."
"Archer's mission is to democratize personalized medicine and eliminating the barriers that stand in the way of the decentralization of testing is part of that mission," said Jason Myers, co-founder and chief executive officer of ArcherDX. "We are excited to be working with Genosity whose founders bring considerable expertise and experience in establishing and operating both cutting edge research and high-volume commercial laboratories. They have developed a compelling and complementary suite of services that will enable our clients to quickly and efficiently implement high quality genomic and genetic tests that can have a profound impact on patient care."
Financial terms of the collaboration are not being disclosed.
ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. By combining patented Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation identification and discovery. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays. Learn more at archerdx.com.
ArcherDX is headquartered in Boulder, Colorado.
Genosity is a life science biotechnology company that employs its expertise, novel software solutions and laboratory services for both somatic and germline applications to enable its strategic partners to fully realize the value of precision medicine for both the research and clinical markets. For more information, please visit us at https://genosity.com/.